New detalimogene bladder cancer data send the minnow’s stock up 47%.
ApexOnco Front Page
Recent articles
The response rate jumps to 30% with higher doses of IMA402.
Redemption of sorts comes for IO Biotech, but there’s no respite for Summit.
But Perspective sinks again.
Amgen and Zai Lab’s FGFR2b antibody shows no benefit at the two-year mark.
Response rates with INCB161734 in pancreatic cancer look in line with Revolution.
The Stellar-303 trial of zanzalintinib hits, but the discussant asks for more data and flags toxicity.
Harmoni-6 succeeds in first-line lung cancer, but the focus is on changes to Harmoni-3.
